Skip to main content
Top
Published in: Critical Care 2/2011

01-04-2011 | Erratum

Erratum to: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

Authors: Benny Sørensen, Donat R Spahn, Petra Innerhofer, Michael Spannagl, Rolf Rossaint

Published in: Critical Care | Issue 2/2011

Login to get access

Excerpt

After publication of our article [1] we noted that in Table 1 for Prothrombinex-VF 'Antithrombin and heparin added' should have been included under the 'Additional information' column. A copy of the table with the correct information can be found overleaf.
Table 1
Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates
   
International units relative to factor IX
   
Brand name
Manufacturer
Factor II
Factor VII
Factor IX
Factor X
Viral inactivation
Additional information
Bebulin VH
Baxter BioScience, Austria
120
(13)
100
100
Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar
Heparin added
Beriplex P/N
CSL Behring, Germany
128
68
100
152
Pasteurisation at 60°C for 10 hours, and nanofiltration
Protein C; antithrombin, heparin and albumin added
Cofact
Sanquin, the Netherlands
56-140
28-80
100
56-140
Solvent/detergent and 15 nm nanofiltration
Antithrombin added
KASKADIL
LFB, France
148
40
100
160
Solvent/detergent
Heparin added
Octaplex
Octapharma, Austria and France
44-152
36-96
100
50
Solvent/detergent and nanofiltration
Heparin added; low activated factor VII content
Profilnine SD
Grifols, USA
148
(11)
100
64
Solvent/detergent
-
Prothrombinex VF
CSL Bioplasma, Australia
100
(-)
100
100
Dry heat, 80°C for 72 hours and nanofiltration
Antithrombin and heparin added
Prothromplex T
Baxter BioScience, Austria
100
85
100
100
Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar
Antithrombin and heparin added
UMAN Complex D.I.
Kedrion, Italy
100
(-)
100
80
Solvent/detergent and dry heat, 100°C for 30 minutes
Antithrombin and heparin added
Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.
Literature
1.
go back to reference Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care. 2011, 15: 201-10.1186/cc9311.PubMedCentralCrossRefPubMed Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care. 2011, 15: 201-10.1186/cc9311.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity
Authors
Benny Sørensen
Donat R Spahn
Petra Innerhofer
Michael Spannagl
Rolf Rossaint
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc10094

Other articles of this Issue 2/2011

Critical Care 2/2011 Go to the issue